ABSTRACT
The presence of sulfur-containing compounds in fuel oil has become a major global issue due to their release of toxic sulfur dioxide. Hydrodesulfurization is a commonly used method for removing sulfur from fuel. However, new desulfurization techniques have been developed recently as hydrodesulfurization (HDS) is ineffective in removing refractory sulfur, e.g., BT, DBT, 4-MDBT. In this study, a series of deep eutectic solvent (DES) using ChCl, salicylic acid, oxalic acid, citric acid, and adipic acid as hydrogen bond acceptors and MeOH, EtOH, BuOH, EG, DEG, and TEG as hydrogen bond donors on different mole ratios were synthesized and then investigated the efficiency of these DESs in extracting sulfur from model and diesel fuel. Densities, viscosity, refractive index, and FTIR spectra of synthesized DESs were recorded. It also included oxidative desulfurization, which is a promising approach offering high selectivity, mild reaction conditions, low cost, and high efficiency. Hydrogen peroxide was selected as the oxidant in this study due to its excellent performance, commercial availability, and high proportion of active oxygen. [Citric acid: TEG] [1:7] and [adipic acid: TEG] [1:8] were found to be the most effective, removing up to 44.07% and 42.53% sulfur from model oil during single-stage extraction at 30 °C using a solvent-to-feed ratio of 1.0 and was increased to 86.87% and 85.06% using successive extraction up to the fourth stage. On oxidation, extraction efficiencies were reported to be 98.98%, 87.79%, and 56.25% and 96.96%, 81.22%, and 44.51% for model oil containing DBT and diesel 1 and diesel 2 with DES [citric acid: TEG] [1:7] and [adipic acid: TEG] [1:8] respectively at 30 °C using a solvent-to-feed ratio of 1.0. The study found that [citric acid: TEG] [1:7] exhibits better extraction performance in the deep desulfurization of fuels at an extraction temperature of 30 °C.
ABSTRACT
Type-1 Diabetes Mellitus (T1DM) manifests due to pancreatic beta cell destruction, causing insulin deficiency and hyperglycaemia. Current therapies are inadequate for brittle diabetics, necessitating pancreatic islet transplants, which however, introduces its own set of challenges such as paucity of donors, rigorous immunosuppression and autoimmune rejection. Organoid technology represents a significant stride in the field of regenerative medicine and bypasses donor-based approaches. Hence this article focuses on strategies enhancing the in vivo engraftment of islet organoids (IOs), namely vascularization, encapsulation, immune evasion, alternative extra-hepatic transplant sites and 3D bioprinting. Hypoxia-induced necrosis and delayed revascularization attenuate organoid viability and functional capacity, alleviated by the integration of diverse cell types e.g., human amniotic epithelial cells (hAECs) and human umbilical vein endothelial cells (HUVECs) to boost vascularization. Encapsulation with biocompatible materials and genetic modifications counters immune damage, while extra-hepatic sites avoid surgical complications and immediate blood-mediated inflammatory reactions (IBMIR). Customizable 3D bioprinting may help augment the viability and functionality of IOs. While the clinical translation of IOs faces hurdles, preliminary results show promise. This article underscores the importance of addressing challenges in IO transplantation to advance their use in treating type 1 diabetes effectively.
